keyword
MENU ▼
Read by QxMD icon Read
search

Ptld liver transplant

keyword
https://www.readbyqxmd.com/read/30017062/incidence-and-survival-rate-of-de-novo-tumors-in-liver-transplants
#1
Carmen Bernal Bellido, Gonzalo Suárez Artacho, José María Álamo Martínez, Luis Miguel Marin Gómez, Carmen Cepeda Franco, Lydia Barrera Pulido, Juan Manuel Praena Fernández, Javier Padillo Ruiz, Miguel Ángel Gómez Bravo
INTRODUCTION: The greater survival of transplanted patients is accompanied by an increase in the rate of de novo malignancies (NM), which are the most frequent late-onset complication. We can distinguish between non-melanoma skin cancers (NMSC), post-transplant lymphoproliferative disorders (PTLD) and solid organ cancers (SOC). Our objective is to determine the incidence of the different types of NM, the time elapsed until diagnosis and survival rates in our setting. METHODS: We conducted a retrospective study of 1071 liver transplant patients from 1990 to 2015 at our center...
July 12, 2018: Cirugía Española
https://www.readbyqxmd.com/read/29997626/dissecting-epstein-barr-virus-specific-t-cell-responses-after-allogeneic-ebv-specific-t-cell-transfer-for-central-nervous-system-posttransplant-lymphoproliferative-disease
#2
Rebecca E Schultze-Florey, Sabine Tischer, Leonie Kuhlmann, Patrick Hundsdoerfer, Arend Koch, Ioannis Anagnostopoulos, Sarina Ravens, Lilia Goudeva, Christian Schultze-Florey, Christian Koenecke, Rainer Blasczyk, Ulrike Koehl, Hans-Gert Heuft, Immo Prinz, Britta Eiz-Vesper, Britta Maecker-Kolhoff
Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disease (PTLD) with central nervous system (CNS) involvement is a severe complication after solid organ transplantation. Standard treatment with reduction of immunosuppression and anti-CD20 antibody application often fails leading to poor outcome. Here, we report the case of an 11-year-old boy with multilocular EBV-positive CNS PTLD 10 years after liver transplantation. Complete remission was achieved by repeated intravenous and intrathecal anti-CD20 antibody rituximab administration combined with intrathecal chemotherapy (methotrexate, cytarabine, prednisone) over a time period of 3 months...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29980871/classical-hodgkin-lymphoma-type-and-monomorphic-type-post-transplant-lymphoproliferative-disorder-following-liver-transplantation-a-case-report
#3
Hiroyuki Kumata, Chikashi Nakanishi, Keigo Murakami, Shigehito Miyagi, Noriko Fukuhara, Joaquim Carreras, Naoya Nakamura, Ryo Ichinohasama, Michiaki Unno, Takashi Kamei, Hironobu Sasano
BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication that can be difficult to treat; moreover, determination of the pathophysiological type is difficult. We report a rare case of a patient who developed two types of Epstein-Barr virus (EBV)-negative PTLD following living donor liver transplantation (LDLT). CASE PRESENTATION: A 64-year-old man underwent LDLT for acute fulminant hepatitis B. Sixty-five months later, he developed EBV-negative monomorphic B cell PTLD...
July 6, 2018: Surgical Case Reports
https://www.readbyqxmd.com/read/29966464/post-transplant-lymphoproliferative-disorders-after-solid-organ-and-hematopoietic-stem-cell-transplantation
#4
Samuel Romero, Juan Montoro, Marta Guinot, Luis Almenar, Rafael Andreu, Aitana Balaguer, Isabel Beneyto, Jordi Espí, José Gómez-Codina, Gloria Iacoboni, Isidro Jarque, Rafael López-Andújar, Empar Mayordomo-Aranda, Joaquín Montalar, Amparo Pastor, Miguel Pastor, José L Piñana, Nohelia Rojas-Ferrer, Ignacio Sánchez-Lázaro, Jesús Sandoval, Guillermo Sanz, Miguel Á Sanz, Amparo Solé, Jaime Sanz
Post-transplant lymphoproliferative disorders (PTLD) are a rare complication after both solid organ (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single center retrospective study, we compared clinical, biological, and histological features, and outcomes of PTLD after both types of transplant. We identified 82 PTLD (61 after SOT and 21 after allo-HSCT). The presence of B symptoms, Waldeyer ring, spleen, central nervous system, and liver involvement, and advanced Ann-Arbor stage were more frequent in allo-HSCT recipients...
July 3, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29893485/treatment-of-pediatric-plasma-cell-myeloma-type-post-transplant-lymphoproliferative-disorder-with-modern-risk-directed-therapy
#5
Rebecca Epperly, John Ozolek, Kyle Soltys, Debra Cohen, Rakesh Goyal, Erika Friehling
Post-transplant lymphoproliferative disorder (PTLD) related plasma cell neoplasms are rare in pediatric patients. We report a pediatric liver transplant recipient with plasma cell myeloma type PTLD. Cytogenetics included 1q duplication, associated with poor prognosis in adult multiple myeloma, and t(8;14). High-risk cytogenetics has not been reported in pediatric plasma cell myeloma type PTLD. The patient was treated with bortezomib, dexamethasone, and lenalidomide with subsequent autologous stem cell transplant...
June 12, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29862092/tumor-necrosis-factor-alpha-inhibition-for-inflammatory-bowel-disease-after-liver-transplant-for-primary-sclerosing-cholangitis
#6
Ravish Parekh, Ahmed Abdulhamid, Sheri Trudeau, Nirmal Kaur
Background: Outcome data regarding the use of tumor necrosis factor alpha inhibitors (anti-TNF α ) in patients with inflammatory bowel disease (IBD) after liver transplant (LT) for primary sclerosing cholangitis (PSC) are scant. Methods: We performed a retrospective chart review to investigate outcomes among a series of post-liver-transplant PSC/IBD patients receiving anti-TNF α therapy at Henry Ford Health System ((HFHS), Detroit, MI). Results: A total of five patients were treated with anti-TNF α agents for IBD after LT for PSC from 1993 through 2015...
2018: Case Reports in Gastrointestinal Medicine
https://www.readbyqxmd.com/read/29755021/a-single-center-experience-of-post-transplant-lymphoproliferative-disorder-ptld-cases-after-pediatric-liver-transplantation-incidence-outcomes-and-association-with-food-allergy
#7
Zeren Barış, Figen Özçay, Özlem Yılmaz Özbek, Nihan Haberal, Faik Sarıalioğlu, Mehmet Haberal
BACKGROUND/AIMS: We evaluated our 16-year single-center experience of pediatric post-transplant lymphoproliferative disorder (PTLD) cases who underwent liver transplantation between 2001 and 2017. MATERIALS AND METHODS: Of the 236 pediatric patients who underwent liver transplantation between 2001 and 2017, the clinical and laboratory data of eight patients diagnosed with PTLD were reviewed. The pre-transplant Epstein-Barr virus (EBV) status of 172 patients was also recorded...
May 2018: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/29743796/increased-incidence-of-post-transplant-lymphoproliferative-disorder-in-autoimmune-liver-disease-an-irish-national-experience
#8
Ahmed Abu-Shanab, Yasser Ged, Naeem Ullah, Diarmaid Houlihan, Aiden McCormick
Background: Post-Transplant Lymphoproliferative Disorder (PTLD) is a well-recognized complication post solid organs transplant. PTLD represents a broad spectrum of abnormalities ranging from an infectious mononucleosis like illness to malignant lymphoma. Methods: A retrospective study was performed by collecting data of orthotopic liver transplant (OLT) patients in the National Liver Unit in Ireland from December 1993 to December 2014. Data was analyzed to identify PTLD patients and determine their demographic details, the indication for liver transplant, presenting symptoms, immunosuppression regimens, Epstein"Barr virus (EBV) status and PTLD outcome...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29703027/multimodality-imaging-features-treatment-and-prognosis-of-post-transplant-lymphoproliferative-disorder-in-renal-allografts-a-case-report-and-literature-review
#9
Jianming Li, Yujiang Liu, Zhenchang Wang, Xiangdong Hu, Ruifang Xu, Linxue Qian
RATIONALE: Among patients with post-transplant lymphoproliferative disorder (PTLD), there is a high incidence of immunosuppressed transplant recipients. It is necessary to make an early diagnosis to increase the likelihood of a good prognosis. PATIENT CONCERNS: We report a case of a 54-year-old female patient who developed PTLD after liver and kidney transplantation. DIAGNOSES: We aimed to analyze the standard diagnosis and follow-up of PTLD with imaging...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29593873/post-transplant-lymphoproliferative-disorder-of-the-bladder-in-a-lung-transplant-recipient
#10
Harpreet Singh Grewal, Charles Lane, Kristin B Highland, Olufemi Akindipe, Marie Budev, Atul C Mehta
Post-transplant lymphoproliferative disorder (PTLD) occurs in ~5% of solid organ and hematopoietic stem cell transplant recipients. We report a unique presentation of PTLD in the bladder of a lung transplant recipient. Our patient was a 62-year-old female who received a bilateral lung transplant for chronic obstructive pulmonary disease. She presented with fever, left-sided flank pain and foul-smelling urine consistent with urosepsis. An abdominal and pelvic computerized tomography revealed an irregular and nodular bladder wall thickening suspicious for urothelial neoplasm...
March 2018: Oxford Medical Case Reports
https://www.readbyqxmd.com/read/29507477/post-transplantation-lymphoproliferative-disorder-with-gastrointestinal-involvement
#11
Faisal Inayat, Ghias Ul Hassan, Ghias Un Nabi Tayyab, Muhammad Wasif Saif
Post-transplantation lymphoproliferative disorders (PTLDs) are lymphoid proliferations or lymphomas that are the second most common tumors in adult transplant recipients. Most cases of PTLD are attributed to Epstein-Barr virus, which induces B-cell proliferation and occurs in the setting of severe immunosuppression after solid organ or bone marrow transplantation. The disorder is seen in 1-3% of liver transplant recipients and has a variable presentation chronology. Herein, we chronicle a case of aggressive B-cell lymphoma (PTLD WHO class-3) presenting with isolated gastrointestinal involvement in an Epstein-Barr virus-negative patient with living-donor liver transplantation, 4 years after receiving the transplant...
March 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29430469/posttransplant-lymphoproliferative-disorder-isolated-to-the-adrenal-gland-in-a-liver-transplant-patient
#12
Tara T Ghaziani, Joy J Liu, Zhenghui G Jiang, Imad Nasser, Khalid Khwaja, Robert A Fisher, Myrna Nahas, Michael P Curry
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication that accounts for up to 20% of malignancies after solid organ transplantation. We describe a rare case of isolated PTLD in the adrenal gland occurring 7 months after liver transplant in a patient who developed a primary Epstein-Barr virus infection. He was treated with rituximab and his immunosuppression regimen was minimized. We review the incidence, pathogenesis, presentation, and management of PTLD in the liver-transplant population...
2018: ACG Case Reports Journal
https://www.readbyqxmd.com/read/29402878/challenges-with-intestine-and-multivisceral-re-transplantation-importance-of-timing-of-re-transplantation-and-optimal-immunosuppression
#13
Chandrashekhar A Kubal, Catherine Pennington, Jonathan Fridell, Burcin Ekser, Plamen Muhaylov, Richard Mangus
BACKGROUND Patients undergoing re-transplantation often receive high doses of immunosuppression, which may lead to an immunocompromised status of the recipient. This study investigates the outcomes after intestine/multivisceral re-transplantation. MATERIAL AND METHODS Clinical outcomes of 23 patients undergoing 24 re-transplantations at a single intestine transplant center were reviewed. Bone marrow suppression was used as a surrogate marker of immunocompromised status, and was defined as platelet count <50 k/mm3 and absolute lymphocyte count <200/mm³...
February 6, 2018: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/29391313/post-transplant-malignancies-in-pediatric-liver-transplant-recipients-experience-of-two-centers-in-turkey
#14
Miray Karakoyun, Şebnem Önen, Maşallah Baran, Murat Çakır, Çiğdem Ömür Ecevit, Murat Kılıç, Mehmet Kantar, Serap Aksoylar, Funda Özgenç, Sema Aydoğdu
BACKGROUND/AIMS: A liver transplant is the preferred treatment for patients with end-stage liver disease, as it usually results in longterm survival. However, due to the use of chronic immunosuppressive therapy, which is necessary to prevent rejection, de novo cancer is a major risk after transplantation. The aim of this study was to assess the incidence of post-transplant malignancies in children after liver transplantations. MATERIALS AND METHODS: The study group consisted of 206 liver transplant recipients, with no history of cancer, including hepatocellular carcinoma, in two liver transplantation centers in Turkey between 1997 and 2015...
January 2018: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/29388302/cytotoxic-t-lymphocyte-therapy-for-post-transplant-lymphoproliferative-disorder-after-solid-organ-transplantation-in-children
#15
Fang Kuan Chiou, Sue V Beath, Gwen M Wilkie, Mark A Vickers, Bruce Morland, Girish L Gupte
EBV-CTL immunotherapy targets EBV antigens expressed by tumor cells in PTLD. Data on outcome of EBV-CTL in pSOT patients are limited. The aim of the study is to describe our experience with allogeneic, third-party EBV-CTL for the treatment of PTLD in pSOT patients in a single tertiary center. Retrospective review was performed of all pSOT patients who received EBV-CTL for PTLD. PTLD was diagnosed using World Health Organization histologic criteria. EBV-CTLs were derived from human leukocyte antigen-typed, EBV-seropositive third-party donors, and cryopreserved and maintained by an accredited national blood transfusion service...
March 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29313699/post-transplant-lymphoproliferative-disease-after-liver-transplantation
#16
COMMENT
José Ignacio Herrero, Carlos Panizo
We have read the article "Post-transplant lymphoproliferative disease in liver transplant recipients" with great interest. This article reports a series of liver transplant recipients with post-transplant lymphoproliferative disease (PTLD). The effect on patient survival and the potential benefit of rituximab-based therapy are highlighted. Rituximab is a chimeric antibody against the CD20 surface marker. This marker is found in most PTLD of a B cell origin. A recent study from our center also highlighted the role of rituximab in PTLD therapy (3)...
February 2018: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/29279693/a-rare-case-of-classical-hodgkin-lymphoma-diagnosed-10-years-after-liver-transplant
#17
L Zhang, R Pereira Mestre, F Bihl, M Bühler, B Vannata, A Stathis
Posttransplant lymphoproliferative disorders (PTLD) represent a rare and potentially life-threatening complication after liver transplantation. Classical Hodgkin lymphoma (cHL), with an incidence of approximately 1.8-3.4% of all PTLD cases, represents a minority of PTLD, mainly presenting as a late transplant complication. The main risk factors for the development of PTLD are Epstein-Barr virus (EBV) infection and intensive immunosuppression. However, other risk factors like hepatitis C virus may, together with EBV infection, contribute to the development of PTLD...
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29103006/a-rare-localised-nasal-cd30-primary-cutaneous-t-cell-lymphoma-following-liver-transplantation
#18
Quan M Nhu, Emma Z Du, Amirali Kiyani, Catherine T Frenette
Cutaneous T-cell post-transplant lymphoproliferative disorder (PTLD) is a rare clinical presentation that can potentially turn aggressive in solid-organ transplant recipients if not detected and intervened on early. We encountered a rare case of rapidly worsening primary cutaneous CD30-positive, Epstein-Barr virus-negative anaplastic large cell lymphoma (ALCL) of T-cell origin, manifesting as an isolated nasal tip lesion in a 71-year-old man 4 years after orthotopic liver transplantation. Excisional biopsy with partial rhinectomy showed subepithelial diffuse infiltration of medium-to-large lymphoid cells having round-to-irregular nuclei, partially condensed chromatin and prominent nucleoli...
November 4, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29094407/a-retrospective-analysis-of-post-transplant-lymphoproliferative-disorder-following-liver-transplantation
#19
Feras Al Fararjeh, Shameem Mahmood, Phaedra Tachtatzis, Deborah Yallop, Stephen Devereux, Piers Patten, Kosh Agrawal, Abid Suddle, John O'Grady, Nigel Heaton, Robert Marcus, Shireen Kassam
OBJECTIVE: To evaluate response rates and survival in adults developing post-transplant lymphoproliferative disorder (PTLD) following liver transplantation. METHODS: Patients were identified retrospectively and data collected through local liver and haematology electronic databases and pharmacy records. RESULTS: Forty-five patients were identified. The median age at first transplant and at development of PTLD was 48 and 54 years, respectively, with the median time from transplant to PTLD diagnosis of 56 months...
January 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29071779/risk-factors-and-clinical-outcomes-of-pediatric-liver-transplant-recipients-with-post-transplant-lymphoproliferative-disease-in-a-multi-ethnic-asian-cohort
#20
James Guoxian Huang, Mervin Ye Qing Tan, Seng-Hock Quak, Marion Margaret Aw
BACKGROUND: We aimed to evaluate clinical characteristics, risk factors, and disease outcomes for liver transplant recipients (LTR) with post-transplant lymphoproliferative disease (PTLD) at our center. METHODS: Retrospective review of data of all pediatric LTR (1991-2015) was conducted. RESULTS: The overall incidence of PTLD was 16.4% (18/110), the majority (13/18) were early lesions, while 3/18 were polymorphic/monomorphic PTLD. The risk factors significant on univariate analysis were as follows: mean age (years) at transplant (1...
February 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
keyword
keyword
163396
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"